The National Institutes of Health (NIH), through its Rapid Acceleration of Diagnostics (RADx) Initiative, announced $248.7 million in awards for seven new COVID-19 diagnostic technologies. The agency estimates that the new technologies could “significantly increase the number, type, and availability of test by millions per week” as early as September 2020.
The NIH details that three of the technologies utilize platforms that provide rapid results at the point of care, such as office, facilities, child care centers, nursing homes, and schools, while the other four technologies leverage innovations in lab-based testing to increase testing capacity and reduce time to test results.
The agency has also collaborated with the Food and Drug Administration (FDA) to pursue emergency use authorization (EUA) and ensure test accuracy.
NIH awarded the following biomedical diagnostic companies:
- Point-of-care tests:
- Mesa Biotech
- Talis Biomedical
- Lab-based tests:
- Ginkgo Bioworks
- Helix OpCo
- Mammoth Biosciences